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Abstract
Background:  Blood lipid levels including low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein
cholesterol (HDL-C), and triglycerides (TG) are highly heritable. Genome-wide association is a promising approach to
map genetic loci related to these heritable phenotypes.
Methods: In 1087 Framingham Heart Study Offspring cohort participants (mean age 47 years, 52% women), we
conducted genome-wide analyses (Affymetrix 100K GeneChip) for fasting blood lipid traits. Total cholesterol, HDL-C,
and TG were measured by standard enzymatic methods and LDL-C was calculated using the Friedewald formula. The
long-term averages of up to seven measurements of LDL-C, HDL-C, and TG over a ~30 year span were the primary
phenotypes. We used generalized estimating equations (GEE), family-based association tests (FBAT) and variance
components linkage to investigate the relationships between SNPs (on autosomes, with minor allele frequency ≥10%,
genotypic call rate ≥80%, and Hardy-Weinberg equilibrium p ≥ 0.001) and multivariable-adjusted residuals. We pursued
a three-stage replication strategy of the GEE association results with 287 SNPs (P < 0.001 in Stage I) tested in Stage II (n
~1450 individuals) and 40 SNPs (P < 0.001 in joint analysis of Stages I and II) tested in Stage III (n~6650 individuals).
Results: Long-term averages of LDL-C, HDL-C, and TG were highly heritable (h2 = 0.66, 0.69, 0.58, respectively; each
P < 0.0001). Of 70,987 tests for each of the phenotypes, two SNPs had p < 10-5 in GEE results for LDL-C, four for HDL-
C, and one for TG. For each multivariable-adjusted phenotype, the number of SNPs with association p < 10-4 ranged from
13 to 18 and with p < 10-3, from 94 to 149. Some results confirmed previously reported associations with candidate
genes including variation in the lipoprotein lipase gene (LPL) and HDL-C and TG (rs7007797; P = 0.0005 for HDL-C and
0.002 for TG). The full set of GEE, FBAT and linkage results are posted at the database of Genotype and Phenotype
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(dbGaP). After three stages of replication, there was no convincing statistical evidence for association (i.e., combined P
< 10-5 across all three stages) between any of the tested SNPs and lipid phenotypes.
Conclusion: Using a 100K genome-wide scan, we have generated a set of putative associations for common sequence
variants and lipid phenotypes. Validation of selected hypotheses in additional samples did not identify any new loci
underlying variability in blood lipids. Lack of replication may be due to inadequate statistical power to detect modest
quantitative trait locus effects (i.e., <1% of trait variance explained) or reduced genomic coverage of the 100K array.
GWAS in FHS using a denser genome-wide genotyping platform and a better-powered replication strategy may identify
novel loci underlying blood lipids.
Introduction
Blood lipid levels are a major contributor to atheroscle-
rotic cardiovascular disease [1]. Current evidence suggests
that blood lipids are complex genetic phenotypes, influ-
enced by both environmental and genetic factors. Herita-
bility estimates for blood lipids are high, including ~40–
60% for high-density lipoprotein cholesterol (HDL-C),
~40–50% for low-density lipoprotein cholesterol (LDL-
C), and ~35–48% for triglycerides (TG) [2]. These esti-
mates indicate that DNA sequence variation plays an
important role in explaining inter-individual variation in
blood lipid levels. Indeed, sequence variants in individual
genes have been consistently related to blood lipid phe-
notypes, including APOE/PCSK9 with LDL-C [3-5], CETP/
LIPC/LPL  with HDL-C [6-9], and APOA5/LPL  with TG
[10,11], among others. However, the extent to which
common genetic variants across the genome account for
total variation in blood lipid levels is unknown.
Recent advances in genomics enable a genome-wide asso-
ciation study (GWAS), an approach in which a substantial
fraction of common genetic variation is tested for a role in
determining phenotypic variation [12]. These advances
include a map of the correlation structure for approxi-
mately 4 million common genetic variants (minor allele
frequency >5%) and whole-genome genotyping technolo-
gies capable of assaying 100,000–500,000 single nucleo-
tide polymorphisms (SNPs) in an individual [13].
Utilizing a fixed genotyping marker set such as the
Affymetrix 100K GeneChip in an association study tests a
substantial fraction of the genome in whites, ~30–45% in
some estimates [14]. GWAS has been successfully applied
to identify novel genetic loci related to several medical
phenotypes including age-related macular degeneration
[15], inflammatory bowel disease [16], and electrocardio-
graphic QT interval [17]. Identifying novel genetic vari-
ants related to blood lipid phenotypes may provide new
drug targets to alter blood lipid levels and may aid in the
prediction of cardiovascular disease.
We hypothesized that common genetic variants explain a
proportion of the inter-individual variability in LDL-C,
HDL-C, and TG. Accordingly, we conducted genome-wide
linkage and association studies for these three phenotypes
in Framingham Heart Study (FHS) participants.
Materials and methods
GWAS sample
Of the 1345 FHS participants who are part of the family
plate set (see Executive Summary), we focused our analy-
ses on the 1087 participants from the Offspring cohort
who had Affymetrix 100K genotypes. Lipid phenotypes
were measured at various examinations as described in
Table 1. Each study participant provided written informed
consent for genetic analyses and the study was approved
by Boston University's Institutional Review Board.
Phenotype definition and methods
Blood lipids were measured from fasting venous blood
collected at each of seven clinical examination time points
extending from 1971 to 2001. Total cholesterol, HDL-C,
and TG were measured by standard enzymatic methods.
LDL-C was calculated using the Friedewald formula, with
a missing value assigned for participants with a measured
TG > 400 mg/dL. Clinical covariates utilized in pheno-
typic regression modeling included age at the time of
blood lipid measurement, age2, body mass index (weight
in kg divided by the height in m2), alcohol intake (drinks
per week), current cigarette smoking (yes, no), menopau-
sal status (postmenopausal yes, no), and hormone
replacement therapy (yes, no).
Commonly-used lipid lowering therapies affect total cho-
lesterol and TG. To account for treatment effect, we
imputed total cholesterol and TG values for those treated
with lipid-lowering therapy. The imputation procedure
was modeled after prior work on imputing blood pressure
values for those on antihypertensive medication [18]. For
each treated individual, a correction factor was added to
the observed [treated] lipid value (total cholesterol or
TG). This correction factor consisted of the difference
between an ''expected'' residual and the ''calculated'' resid-
ual. The ''calculated'' residual for each individual was gen-
erated in a sex-specific manner after adjustment for age,
age2, age3, and examination year (by decade). The
''expected'' residual was generated within each sex and 10
year-age-group as the average of ''calculated'' residualsBMC Medical Genetics 2007, 8(Suppl 1):S17 http://www.biomedcentral.com/1471-2350/8/S1/S17
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Table 1: Lipid Phenotypes Examined Using Affymetrix 100K GeneChip Scan
Phenotype Acronym Phenotypes N h2 * Offspring Exam Adjustment† Multivaria-
ble model
Total cholesterol TC 7 1069 0.57‡ 1,2,3,4,5,6,7 Age, age2, smoking, body 
mass index, alcohol 
consumption, menopausal 
status, hormone replacement 
therapy; Covariate-adjusted 
residuals created separately 
by gender
Low-density lipoprotein 
cholesterol
LDL-C 7 1056 0.59‡ 1,2,3,4,5,6,7
High-density lipoprotein 
cholesterol
HDL-C 7 1062 0.52‡ 1,2,3,4,5,6,7
Triglycerides TG 7 1068 0.48‡ 1,2,3,4,5,6,7
Mean total cholesterol MeanTC 1 1087 0.61 Avg of Exams 1,2,3,4,5,6,7
Mean low-density 
lipoprotein cholesterol
MeanLDL-C 1 1086 0.66 Avg of Exams 1,2,3,4,5,6,7
Mean high-density 
lipoprotein cholesterol
MeanHDL-C 1 1087 0.69 Avg of Exams 1,2,3,4,5,6,7
Mean triglycerides MeanTG 1 1087 0.58 Avg of Exams 1,2,3,4,5,6,7
Apolipoprotein A-I ApoA-I 1 997 0.42 4
Apolipoprotein B ApoB 1 997 0.47 4
Apolipoprotein C3 ApoC3 1 767 0.38 4
Apolipoprotein E ApoE 1 744 0.54 5
High-density lipoprotein 2 
cholesterol
HDL2-C 2 955 (exam 4) 958 
(exam 5)
0.50 0.53 4,5
High-density lipoprotein 3 
cholesterol
HDL3-C 2 984 (exam 4) 1020 
(exam 5)
0.48 0.54 4,5
Large high-density 
lipoprotein by NMR
HDLNMRlg 1 851 0.53 4
Intermediate high-density 
lipoprotein by NMR
HDLNMRint 1 851 0.22 4
Small high-density 
lipoprotein by NMR
HDLNMRsm 1 851 0.24 4
High-density lipoprotein 
particle size by NMR
HDLNMRsz 1 851 0.50 4
Intermediate-density 
lipoprotein particle by 
NMR
IDLNMR 1 851 0.20 4
Large low-density 
lipoprotein by NMR
LDLNMRlg 1 851 0.39 4
Small low-density 
lipoprotein by NMR
LDLNMRsm 1 851 0.40 4
Low-density lipoprotein 
particle size by NMR
LDLNMRsz 1 851 0.40 4
Large very low-density 
lipoprotein particle by 
NMR
VLDLNMRlg 1 851 0.34 4
Intermediate very low-
density lipoprotein particle 
by NMR
VLDLNMRint 1 878 0.40 4
Small very low-density 
lipoprotein particle by 
NMR
VLDLNMRsm 1 851 0.24 4
Very low-density 
lipoprotein particle size by 
NMR
VLDLNMRsz 1 851 0.42 4
Triglyceride/high-density 
lipoprotein cholesterol 
ratio
tghdl 7 1060 0.56‡ 1,2,3,4,5,6,7
Total cholesterol/high-
density lipoprotein 
cholesterol ratio
cholhdl 7 1060 0.58‡ 1,2,3,4,5,6,7
Lipoprotein(a) Lp(a) 1 763 0.90 3
Remnant lipoprotein 
cholesterol
RLP-C 1 746 0.34 4
Remnant lipoprotein 
triglycerides
RLP-TG 1 715 0.33 4
Note: TG, MeanTG, cholhdl, and tghdl were natural log transformed due to skewed distribution;
*Heritability (h2) estimates presented are those after multivariable-adjustment; P < 0.0001 for all heritability estimates.
†Each phenotype had 2 adjustment schemes: age- and sex-adjusted and multivariable-adjusted. Both age- and sex-adjusted and multivariable-adjusted model results are web 
posted.
‡Heritability estimates were derived from lipid phenotypes at a single time-point, that of FHS Examination 1.BMC Medical Genetics 2007, 8(Suppl 1):S17 http://www.biomedcentral.com/1471-2350/8/S1/S17
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equal or greater than the treated individual's ''calculated''
residual.
Lipoprotein subclass profiles were measured by a com-
mercially available proton NMR spectroscopic assay
(LipoScience, Raleigh, NC) on plasma samples stored at -
70°C as described previously [19]. The particle concentra-
tion of the following 9 lipoprotein species were deter-
mined: 3 VLDL subclasses [large, >60 nm (including
chylomicrons); intermediate, 35–60 nm; small, 27–35
nm]; 3 LDL subclasses (IDL, 23–27 nm; large LDL 21.3–
23 nm; small LDL, 18.3–21.2 nm); and 3 HDL subclasses
(large, 8.8–13 nm; intermediate, 8.2–8.8 nm; small, 7.3–
8.2 nm). The small LDL subclass comprises the sum of
subclasses formerly labeled "intermediate" (19.8–21.2
nm) and "small" (18.3–19.7 nm) [19], since concentra-
tions of both have very similar relations to lipid levels.
Genotyping methods
All analyses were based on the Affymetrix 100K GeneChip
genotyping data generated in Framingham Heart Study
participants as described previously [20]. In order to min-
imize false positive associations due to genotyping arti-
fact, we limited our analyses to SNPs with a genotyping
call rate ≥80% and a Hardy-Weinberg Equilibrium P ≥
0.001. Given lower statistical power to detect associations
with rarer SNPs, we limited our results to SNPs with a
minor allele frequency ≥10%.
Statistical analysis methods
TG levels were log-transformed to approximate a normal
distribution. For each blood lipid phenotype, the long-
term average of 4 to 7 serial measurements was used as the
primary phenotype. Participants contributing fewer than
4 of 7 measures of a given phenotype were excluded from
that analysis. MeanLDL-C, MeanHDL-C, and MeanTG
were adjusted for covariates in sex-specific linear regres-
sion models. Two sets of phenotypic models were created:
Model 1 (age, age2) and Model 2 (age, age2, body mass
index, alcohol intake, cigarette smoking, menopausal sta-
tus, and hormone replacement therapy). For quantitative
covariates (age, body mass index, and alcohol intake), the
mean value across examinations was used as a covariate.
For categorical covariates, the proportion of exams scored
as 'yes' was used. The residual MeanLDL-C, MeanHDL-C,
and MeanlogTG values from Model 1 and Model 2 served
as the primary phenotypes.
For genotype-phenotype association analyses, we
assumed an additive model of inheritance. We conducted
multivariable linear regression using GEE, family-based
association testing using FBAT, and linkage using Merlin
for computation of IBDs and SOLAR for variance compo-
nent models as described in the Executive Summary.
Heritability analyses
Heritability estimates for the lipid phenotypes were
obtained from extended families with at least two mem-
bers by variance-components methods using the Sequen-
tial Oligogenic Linkage Analysis Routines (SOLAR)
package [21]. Using this approach, maximum-likelihood
estimation was applied to a mixed-effects model that
incorporated fixed covariate effects, additive genetic
effects, and residual error. The additive genetic effects and
residual errors were assumed to be normally distributed
and to be mutually independent. The analyses were per-
formed using residuals from the multivariable models
(Model 1 and Model 2) mentioned above. For pheno-
types with kurtosis > 1, heritability estimates were com-
puted on ranked normalized deviates.
Replication samples
Replication genotyping was attempted in three independ-
ent sample sets: a) the FHS unrelated plate set; b) Genetics
of Lipid Lowering Drugs and Diet Network (GOLDN);
and c) Malmö Diet and Cancer Study – Cardiovascular
Cohort (MDC-CC).
The second stage consisted of ~1450 biologically unre-
lated individuals from the FHS unrelated plate set. The
third stage consisted of ~1450 participants from GOLDN
and ~5200 participants from MDC-CC. GOLDN is a fam-
ily-based sample recruited from two National Heart,
Lung, and Blood Institute's Family Heart Study field cent-
ers (Minneapolis, MN and Salt Lake City, UT). The Family
Heart Study is a multi-center, population-based cohort
designed to study the genetic and environmental determi-
nations of cardiovascular disease.
The MDC study is a community-based prospective epide-
miologic cohort of 28,098 persons recruited for a baseline
examination between 1991 and 1996. From this cohort,
6103 persons were randomly selected to participate in the
MDC-CC which sought to investigate risk factors for car-
diovascular disease. Of the MDC-CC participants, 5466
had DNA and lipid phenotypes available. Individuals on
lipid lowering therapy and with outlier values of LDL-C,
HDL-C, or TG (top 0.5% of the distribution) were
excluded, leaving 5212 individuals available for the SNP-
lipid association analyses
Staged replication strategy
For follow-up into Stage II (the FHS unrelated plate set),
we selected all SNPs in the GWAS with an association P <
0.001 for the MeanLDL-C, MeanHDL-C, or MeanTG phe-
notypes from the minimally-adjusted phenotypic model
(Model 1, adjustment for age, age2 only). We next con-
ducted a joint analysis of Stage I (GWAS 100K data) and
Stage II (FHS unrelated plate set). The joint analysis con-
sisted of a weighted average of the beta estimates andBMC Medical Genetics 2007, 8(Suppl 1):S17 http://www.biomedcentral.com/1471-2350/8/S1/S17
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standard errors from Stages I and II and used the inverse
of the variance in each stage as weights.
For follow-up into Stage III (GOLDN and MDC-CC), we
selected for genotyping all SNPs with a P < 0.001 in the
joint analysis of Stages I and II. For genotype-phenotype
association analyses in MDC-CC and GOLDN, we
assumed an additive model of inheritance. In MDC-CC,
we conducted multivariable linear regression analyses to
test the null hypothesis that LDL-C, HDL-C, or TG residu-
als (sex-specific residuals adjusted for age and age2) did
not differ by increasing minor allele copy number. In
GOLDN, to account for correlated observations due to
family relationships we used linear mixed-effects methods
in SOLAR.
To summarize the statistical evidence for association for
each SNP across all three stages, we reiterated the
weighted average beta-estimates and standard errors as
described above.
Results
Clinical characteristics of the FHS sample of 1345 subjects
are presented in the Executive Summary. Table 1 displays
the variables that were studied in our analyses of lipid
phenotypes. Further information on these phenotypes
can be found at http://www.ncbi.nlm.nih.gov/projects/
gap/cgi-bin/study.cgi?id=phs000007. Since Original
cohort members were non-fasting at examination, our
analyses considered only the 1087 Offspring Study partic-
ipants with fasting lipid measurements and Affymetrix
100K SNP genotypes. For this paper we focus on longitu-
dinal mean levels of serially measured values (minimum
of 4, maximum of 7) of LDL-C, HDL-C, and TG (labeled
MeanLDL-C, MeanHDL-C, and MeanTG).
Heritability estimates for long-term average lipid pheno-
types (Mean LDL-C, MeanHDL-C, and MeanTG) were
greater than those from single time-point measurements
(Table 1). For example, the heritabilities of MeanLDL-C,
MeanHDL-C, and MeanTG were 0.66, 0.69, and 0.58,
respectively, whereas heritabilities for LDL-C, HDL-C, and
TG measured at FHS Examination 1 (a single time-point)
were 0.59, 0.52, and 0.48, respectively. The highest herit-
ability estimate for any available lipid phenotype was that
for lipoprotein (a) at 0.90.
From the GEE analyses, the strongest associations for
MeanLDL-C, MeanHDL-C, and MeanTG were for SNPs
rs287474 (p = 6.3*10-9), rs524802 (p = 7.6*10-7), and
rs7007075 (p = 7.7*10-6), respectively (Table 2a). From
the FBAT analyses, the strongest associations for Mean-
LDL-C, MeanHDL-C, and MeanTG were for SNPs
rs287474 (p = 1.4*10-8), rs10495594 (p = 5.1*10-5), and
rs1449866 (p = 1.8*10-5), respectively (Table 2b). For
each multivariable-adjusted phenotype, the number of
SNPs with a GEE association p < 10-4 ranged from 13 to 18
and with p < 10-3, from 94 to 149. The number of SNPs
with FBAT association p < 10-4 ranged from 2 to 5 and
with p < 10-3, from 74 to 79.
Linkage LOD scores > 2.0 are presented in Table 2c. The
best evidence for linkage was a peak LOD score of 3.3 on
chromosome 7 for the MeanHDL-C phenotype.
Because the prior probability of any SNP relating to a phe-
notype is low and given the number of tests, the P value
distribution in a GWAS should approach a null distribu-
tion. Any strong departure from this expectation might
suggest artifacts in genotyping or analysis. For the 70,987
SNPs that passed quality-control filters, the distribution of
association P values (generated by the GEE methodology)
approached a null distribution but with a slight excess of
low P values. For example, for the MeanLDL-C, whereas
one would expect 1% of SNPs to demonstrate a P < 0.01
by chance, we found that 1.34% of SNPs displayed a P <
0.01. Similar results were seen for meanHDL-C and
meanTG (data not shown).
We evaluated the association results for a SNP and each of
a set of four correlated phenotypes – ApoA-I, LDLNMRsm,
MeanHDL-C, and MeanTG (Table 3). Several SNPs were
associated with P < 0.01 for 3 of the 4 phenotypes.
Among the GEE association results, a SNP (rs7007797) in
the lipoprotein lipase (LPL) was associated with Mean-
HDL-C (p = 0.0005) and MeanTG (p = 0.002) (Table 4).
This SNP is a perfect proxy (r2 = 1) to the previously stud-
ied rs328 (also known as S447X) [22]. The minor allele of
rs328 has been consistently related to higher HDL-C and
lower TG. The direction of effect for SNP rs7007797 in our
dataset was consistent with previous observations. Due to
a lack of SNPs in the Affymetrix 100K GeneChip corre-
lated with previously reported variants (at r2 > 0.5 thresh-
old) in the APOE, PCSK9, CETP, LIPC, and APOA5 genes,
we were unable to confirm these other previously
reported associations (Table 4).
Replication is critical to distinguish true positives from
false ones in a GWAS. We pursued a three-stage replica-
tion strategy with 287 SNPs (P < 0.001 in Stage I) tested in
Stage II (n~1450 individuals) and 40 SNPs (P < 0.001 in
joint analysis of Stages I and II) tested in Stage III (n~6650
individuals). Results are displayed in Table 5. After three
stages of replication, there was no convincing statistical
evidence for association (i.e. joint analysis stages I, II & III
P < 10-5) between any of the tested SNPs and lipid pheno-
types.BMC Medical Genetics 2007, 8(Suppl 1):S17 http://www.biomedcentral.com/1471-2350/8/S1/S17
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Table 2: Overview of Top Association and Linkage Results for MeanLDL-C, MeanHDL-C, and MeanTG
2a. Top 25 SNPs for association with MeanLDL-C, MeanHDL-C, or MeanTG based on the lowest p values of the GEE tests
Phenotype SNP rs ID* Chr Physical location (bp) GEE P-value FBAT P-value gene (IN or NEAR)
MeanLDL-C rs287474 13 68173961 6.3*10-9 1.4*10-8
MeanLDL-C rs287354 13 68137953 3.4*10-8 6.8*10-8
MeanHDL-C rs524802 19 42138787 7.6*10-7 0.04
MeanHDL-C rs505717 19 42122156 1.2*10-6 0.07 ZNF345
MeanHDL-C rs544543 19 42122663 2.5*10-6 0.07
MeanTG rs7007075 8 138168448 7.7*10-6 0.004
MeanHDL-C rs3734678 6 107639853 8.2*10-6 0.009 C6orf210
MeanLDL-C rs10488824 11 81678287 1.4*10-5 0.03
MeanTG rs2142136 10 89753050 1.5*10-5 0.06 BC005821| PTEN
MeanLDL-C rs1555173 6 85121177 1.7*10-5 0.09
MeanHDL-C rs688933 9 70902713 1.8*10-5 0.38 TRPM3| AJ505026| AL136545
MeanTG rs314474 11 11482634 1.8*10-5 0.09 AB094146| IGSF4| BC047021
MeanHDL-C rs966376 18 27086836 2.1*10-5 0.07
MeanHDL-C rs4459845 3 127400326 2.3*10-5 0.005 ALDH1L1| CR749807
MeanTG rs220840 11 114826173 2.5*10-5 0.09 AB094146| IGSF4| BC047021
MeanHDL-C rs3850301 14 58150885 2.8*10-5 8.6*10-4 BX161433| DACT1
MeanLDL-C rs1317538 6 73706132 3.0*10-5 0.02 BC050689| KCNQ5
MeanHDL-C rs7021834 9 71123639 3.0*10-5 0.003 AL136545
MeanLDL-C rs504527 1 34142701 3.2*10-5 0.007 CSMD2
MeanHDL-C rs10488779 11 79494759 3.6*10-5 0.07
MeanLDL-C rs2415621 14 40114277 3.8*10-5 0.005
MeanHDL-C rs10508518 10 17081479 3.9*10-5 0.09 CUBN
MeanLDL-C rs1245058 1 69760085 4.1*10-5 0.004 LRRC7
MeanHDL-C rs10488780 11 79490000 4.4*10-5 0.06
MeanHDL-C rs541326 9 70936505 4.5*10-5 0.39 TRPM3| AJ505026| AL136545
2b. Top 25 SNPs for association with MeanLDL-C, MeanHDL-C, or MeanTG based on the lowest p values of the FBAT tests
Phenotype SNP rs ID* Chr Physical location (bp) GEE P-value FBAT P-value gene (IN or NEAR)
MeanLDL-C rs287474 13 68173961 1.4*10-8 6.3*10-9
MeanLDL-C rs287354 13 68137953 6.8*10-8 3.4*10-8
MeanTG rs1449866 3 144359331 1.8*10-5 0.002 CHST2| AK131346
MeanTG rs10506354 12 57759034 2.2*10-5 0.007
MeanTG rs10494989 1 211576634 2.4*10-5 4.7*10-4 AY552981| AK123409| KCNK2
MeanTG rs2371978 12 57759239 2.4*10-5 0.01
MeanHDL-C rs10495594 2 12280997 5.1*10-5 1.8*10-4
MeanHDL-C rs10495593 2 12279945 5.1*10-5 1.8*10-4
MeanLDL-C rs1411931 1 37451967 5.8*10-5 0.03
MeanLDL-C rs10516433 4 99800704 7.7*10-5 0.03 TSPAN5
MeanHDL-C rs2182114 1 111496269 8.2*10-5 0.07 CHI3L2
MeanTG rs1835353 2 124880057 8.3*10-5 0.02 CNTNAP5| AK056528
MeanLDL-C rs10516434 4 99802493 8.6*10-5 0.03 TSPAN5
MeanLDL-C rs10507755 13 68355991 1.1*10-4 1.6*10-4
MeanLDL-C rs6853079 4 99800789 1.3*10-4 0.06 TSPAN5
MeanHDL-C rs1508116 2 41437773 1.3*10-4 0.07
MeanLDL-C rs10518072 4 71271418 1.4*10-4 0.05 APIN| C4orf7| CSN3
MeanTG rs715260 4 9804415 1.5*10-4 0.002 WDR1
MeanTG rs7784056 7 77762038 1.6*10-4 0.12 AB014605| MAGI2
MeanHDL-C rs6505623 18 1115057 1.6*10-4 0.006
MeanHDL-C rs1541296 18 59173095 1.6*10-4 0.02 FVT1
MeanHDL-C rs6821328 4 54058427 1.7*10-4 0.02 SCFD2
MeanTG rs1501572 9 2894794 1.7*10-4 1.1*10-4
MeanTG rs4684343 3 2366098 1.8*10-4 0.24 CNTN4
MeanTG rs225634 6 142518312 1.9*10-4 2.4*10-4 C6orf55
2c. Magnitude and Location of Peak LOD scores > 2.0 for MeanLDL-C, MeanHDL-C, and MeanTG
Phenotype Exam Chr Physical location (Mb) Maximum LOD LOD-1.5 Interval LOD+1.5 Interval
MeanHDL-C 1–7 7 33485983 3.30 27810820 36074331
MeanLDL-C 1–7 9 94130181 2.83 88057135 98516033
MeanTG 1–7 1 153444389 2.73 151582274 155505440
MeanLDL-C 1–7 3 196384998 2.12 187706181 199138789
Chr = chromosomeBMC Medical Genetics 2007, 8(Suppl 1):S17 http://www.biomedcentral.com/1471-2350/8/S1/S17
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Discussion
We examined associations of Affymetrix 100K SNPs and
lipid traits in FHS and identified putative associations
with lipid phenotypes. We studied the long-term average
of up to 7 measurements each of LDL-C, HDL-C, and TG
as the primary phenotypes and for one phenotype, the
MeanLDL-C, we observed a nominal P that exceeded
genome-wide significance [13]. However, validation of
selected hypotheses in additional samples did not identify
any new loci underlying variability in blood lipids.
GWAS offers the potential to identify novel genetic vari-
ants/loci that are associated with blood lipid variation,
unlimited by our current knowledge of lipoprotein biol-
ogy. However, a central limitation of GWAS is that the
true signals are mixed amidst a large number of false pos-
itive results. Validation in additional samples is required
to distinguish the true positives from the false ones.
Replication of initial GWAS findings using a staged design
has been suggested to minimize genotyping cost and max-
imize statistical power [23,24]. An important considera-
tion in such a design is the proportion of markers taken
forward to a second stage. We estimated the statistical
power for our three-stage GWAS strategy. Assuming a
modest number of markers (all SNPs with P < 0.001 for
each phenotype, ~0.1% of markers) are taken forward to
Stage II, a second stage sample size of 1450, that SNPs
with P < 0.001 are taken forward from Stage II to Stage III,
a stage III sample size of 6650, and that the final alpha
(after Stages I, II, & III) is set at a conservative 5*10-8, we
estimated that we had 89% power to detect a quantitative
Table 4: Comparison with the prior literature
Gene Phenotype Selected SNPs 
previously associated 
with phenotype
# SNPs in Affymetrix 
100K within 60 kb of 
gene
# SNPs in Affymetrix 100K 
within 60 kb of Gene Locus 
and with r2 > 0.5 to previously 
reported SNP
SNP in Affymetrix 
100K (r2 to previously 
reported SNP)
p for association in 
FHS 100K
APOE LDL-C rs429358
rs7412
10- -
PCSK9 LDL-C rs11591147 7 0 - -
CETP HDL-C rs1800775 2 0 - -
LIPC HDL-C rs1800588 18 0 - -
LPL HDL-C rs328 8 2 rs10503669 (r2 = 1.0)
rs7007797 (r2 = 1.0)
rs10503669 – 9.1*10-4
rs7007797 – 5.0*10-4
LPL TG rs328 8 2 rs10503669 (r2 = 1.0)
rs7007797 (r2 = 1.0)
rs10503669 – 0.02
rs7007797 – 0.002
APOA5 TG rs662799
rs3135506
40- -
Table 3: GEE results for 4 correlated phenotypes (ApoA-I, LDLNMRsm, MeanHDL-C, and MeanTG), ranked by proportion of GEE P < 
0.01*
rs id Chr Physical Position GEE P ApoA-I GEE P LDLNMRsm GEE P MeanHDL-C GEE P MeanTG Gene Symbol
rs505717 19 42122156 7.8*10-4 0.003 1.3*10-6 0.04 ZNF568
rs3734678 6 107639853 4.7*10-4 0.18 8.2*10-6 0.006 PDSS2
rs2256038 21 15443047 0.11 0.002 8.8*10-4 6.4*10-5
rs10486788 7 15788581 4.7*10-4 0.005 8.5*10-4 0.01
rs232885 1 58824078 0.86 0.002 9.6*10-4 5.7*10-4 AB067502
rs4982795 14 23294875 0.001 1.9*10-7 0.001 0.11
rs524802 19 42138787 0.001 0.003 7.6*10-7 0.02 ZNF568
rs544543 19 42122663 0.001 0.004 2.5*10-4 0.03 ZNF568
rs2823097 21 15445015 0.10 0.004 0.002 8.0*10-5
rs1394041 3 148579545 0.02 0.003 0.002 5.6*10-5
rs10499320 7 2906624 0.001 0.001 8.8*10-4 0.03
rs2889195 1 65868751 6.6*10-4 0.003 0.003 0.02
rs7007797 8 19921250 0.01 0.02 5.0*10-4 0.002
rs7597861 2 100311705 0.08 0.004 1.0*10-4 0.006
rs6063858 20 50715959 0.04 3.0*10-4 0.002 0.003
rs2425524 20 40750358 0.01 0.05 3.6*10-4 0.008
rs1509384 2 22556488 8.5*10-4 0.01 0.007 0.03
rs9317760 13 68480686 0.003 0.05 6.6*10-4 0.002
rs6804032 3 116031161 0.002 0.02 0.009 8.7*10-4
rs8069913 17 13812167 0.03 0.009 0.001 6.7*10-4
*All SNPs in this table had GEE association P values < 0.01 for at least three of the four traits (ApoA-I, LDLNMRsm, MeanHDL-C, and MeanTG). No SNPs in our dataset had 
GEE association P values < 0.01 for all four traits.B
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Table 5: Association Results for 40 SNPs Attempted for Replication in Three Stages
SNP Chr Gene Allele* Trait Stage I – FHS 100K Stage II – FHS Unrelated Joint P Stage III – MDC Stage III – GOLDN Joint Stages I, II, & III
PB e t a † SE P Beta SE Stages I & II P Beta SE P Beta SE P Beta SE
rs7231460 18 C MeanHDL-C 4.3*10-4 -0.145 0.041 2.4*10-4 -0.131 0.036 3.7*10-7 0.50 0.013 0.020 0.60 0.023 0.044 0.03 -0.033 0.015
rs966376 18 C MeanHDL-C 2.5*10-4 -0.148 0.040 4.8*10-4 -0.125 0.036 4.5*10-7 0.43 0.016 0.020 0.56 0.026 0.044 0.04 -0.031 0.015
rs744134 13 L10374 C MeanLDL-C 5.4*10-4 0.168 0.048 4.7*10-4 0.124 0.036 1.1*10-6 0.67 0.009 0.020 0.20 0.062 0.048 0.0007 0.053 0.016
rs7233386 18 T MeanHDL-C 2.4*10-4 0.149 0.041 0.005 0.100 0.036 6.3*10-6 0.32 -0.020 0.020 0.61 -0.023 0.046 0.11 0.024 0.015
rs1428445 5 A MeanHDL-C 3.0*10-4 -0.187 0.052 0.01 -0.113 0.044 1.8*10-5 0.24 -0.028 0.024 0.77 0.016 0.054 0.002 -0.058 0.018
rs2304589 2 LOC130502 A MeanLDL-C 6.4*10-4 0.187 0.055 0.006 0.124 0.045 1.8*10-5 0.47 -0.020 0.027 0.09 -0.101 0.060 0.18 0.027 0.020
rs2278528 2 LOC130502 G MeanLDL-C 6.7*10-4 0.180 0.053 0.007 0.122 0.045 2.0*10-5 0.51 -0.018 0.027 0.12 -0.092 0.060 0.14 0.029 0.020
rs2142136 10 PTEN G MeanTG 8.1*10-6 0.228 0.051 0.14 0.077 0.052 2.4*10-5 0.38 -0.026 0.029 0.85 0.011 0.061 0.06 0.040 0.021
rs1555173 6 C MeanLDL-C 1.0*10-5 -0.243 0.055 0.10 -0.083 0.050 2.7*10-5 0.31 -0.027 0.027 0.03 0.143 0.066 0.01 -0.051 0.021
rs6053754 20 FLJ25067 C MeanLDL-C 3.1*10-4 0.166 0.046 0.02 0.090 0.037 3.4*10-5 0.46 0.017 0.022 0.99 -0.001 0.050 0.003 0.049 0.017
rs8032553 15 KIF7 A MeanLDL-C 3.0*10-5 0.171 0.041 0.08 0.061 0.034 5.5*10-5 0.09 0.033 0.020 Failed Failed Failed 0.0002 0.060 0.016
rs1741662 6 RFXDC1 T MeanTG 7.2*10-5 0.198 0.050 0.07 0.083 0.046 5.9*10-5 0.15 -0.037 0.026 0.03 -0.131 0.061 0.58 0.011 0.020
rs1741660 6 RFXDC1 T MeanTG 7.8*10-5 0.197 0.050 0.07 0.084 0.046 6.1*10-5 Failed‡ Failed Failed Failed Failed Failed 6E-05 0.136 0.034
rs890945 5 A MeanHDL-C 5.4*10-4 -0.181 0.052 0.03 -0.099 0.044 8.0*10-5 0.18 -0.033 0.024 0.79 0.014 0.053 0.002 -0.057 0.018
rs10512297 9 T MeanLDL-C 2.1*10-4 -0.235 0.064 0.05 -0.108 0.054 8.6*10-5 0.71 -0.011 0.030 0.44 0.056 0.072 0.03 -0.051 0.023
rs541326 9 TRPM3 G MeanHDL-C 3.6*10-5 -0.201 0.049 0.28 -0.061 0.056 1.3*10-4 0.10 0.048 0.029 0.02 -0.159 0.069 0.08 -0.038 0.022
rs719829 5 G MeanTG 1.3*10-4 -0.156 0.041 0.11 -0.062 0.039 1.4*10-4 0.66 0.009 0.022 0.58 0.028 0.050 0.08 -0.028 0.016
rs10509384 10 KCNMA1 G MeanLDL-C 7.7*10-4 -0.148 0.044 0.04 -0.076 0.038 1.9*10-4 0.02 0.050 0.021 Failed Failed Failed 0.79 -0.005 0.017
rs688933 9 TRPM3 T MeanHDL-C 3.1*10-6 -0.232 0.050 0.80 -0.015 0.059 2.0*10-4 0.17 0.041 0.030 0.01 -0.172 0.069 0.05 -0.044 0.022
rs1122080 5 A MeanHDL-C 3.4*10-4 -0.202 0.056 0.07 -0.084 0.047 2.5*10-4 0.44 -0.020 0.025 0.47 -0.041 0.058 0.005 -0.055 0.019
rs6743779 2 KLF7 C MeanLDL-C 2.4*10-5 -0.181 0.043 0.24 -0.043 0.036 2.8*10-4 0.69 0.009 0.022 Failed Failed Failed 0.05 -0.033 0.017
rs950828 4 A MeanHDL-C 9.1*10-4 -0.151 0.046 0.06 -0.080 0.043 2.9*10-4 0.58 0.012 0.022 Failed Failed Failed 0.10 -0.030 0.018
rs1365032 8 C MeanLDL-C 1.4*10-4 -0.161 0.042 0.12 -0.053 0.034 3.2*10-4 0.01 -0.056 0.020 0.11 0.077 0.048 0.0002 -0.055 0.015
rs287474 13 T MeanLDL-C 8.1*10-6 0.209 0.047 0.16 0.056 0.040 3.4*10-4 0.97 0.001 0.020 0.62 -0.023 0.046 0.05 0.030 0.016
rs10507756 13 C MeanLDL-C 6.0*10-5 0.202 0.050 0.22 0.052 0.043 4.2*10-4 0.24 0.032 0.028 0.89 -0.008 0.060 0.003 0.059 0.020
rs1507203 13 C MeanLDL-C 1.9*10-4 0.172 0.046 0.15 0.057 0.039 4.3*10-4 0.23 0.027 0.023 0.32 -0.052 0.052 0.01 0.044 0.017
rs4941236 18 SERPINB8 C MeanLDL-C 4.7*10-4 0.151 0.043 0.09 0.059 0.034 4.3*10-4 0.83 -0.004 0.020 0.18 -0.065 0.048 0.02 0.022 0.015
rs544543 19 G MeanHDL-C 4.8*10-6 -0.185 0.040 0.61 -0.019 0.038 4.7*10-4 0.95 -0.001 0.021 0.78 -0.013 0.047 0.03 -0.033 0.016
rs3763188 6 REPS1 C MeanTG 5.2*10-4 -0.191 0.055 0.12 -0.076 0.048 5.1*10-4 0.13 0.042 0.028 0.02 -0.153 0.063 0.09 -0.035 0.021
rs717987 6 RUNX2 G MeanHDL-C 8.0*10-5 0.250 0.063 0.26 0.063 0.057 5.4*10-4 0.06 0.058 0.031 0.87 0.011 0.067 0.0007 0.079 0.023
rs10508997 10 G MeanTG 4.1*10-4 -0.165 0.047 0.15 -0.062 0.043 5.6*10-4 0.10 0.039 0.023 Failed Failed Failed 0.51 -0.012 0.019
rs2395833 7 PRKAR2B T MeanHDL-C 6.2*10-4 -0.145 0.042 0.12 -0.060 0.038 5.6*10-4 0.99 0.000 0.021 0.06 -0.090 0.049 0.01 -0.041 0.016
rs6677589 1 JUN G MeanTG 1.9*10-4 -0.145 0.039 0.27 -0.042 0.037 7.1*10-4 0.18 0.028 0.021 0.84 -0.010 0.048 0.30 -0.016 0.016
rs10513320 3 A MeanTG 1.3*10-4 -0.190 0.050 0.31 -0.046 0.045 9.0*10-4 0.24 0.028 0.024 0.21 0.068 0.054 0.61 -0.010 0.018
rs508969 18 CETN1 A MeanLDL-C 6.8*10-4 -0.144 0.042 0.18 -0.053 0.040 9.5*10-4 0.31 0.023 0.023 0.64 0.025 0.054 0.29 -0.018 0.017
rs7858099 9 G MeanLDL-C 6.9*10-4 -0.140 0.041 0.15 -0.051 0.035 9.6*10-4 0.53 -0.013 0.021 0.31 -0.049 0.048 0.006 -0.043 0.016
rs4134425 14 T MeanLDL-C 6.6*10-4 -0.156 0.046 0.13 -0.055 0.036 9.8*10-4 0.14 0.032 0.021 0.16 -0.068 0.048 0.24 -0.019 0.016
rs7021834 9 AL136545 T MeanHDL-C 4.3*10-5 -0.174 0.043 0.65 -0.021 0.045 9.9*10-4 0.05 0.045 0.023 1.00 0.000 0.057 0.72 -0.006 0.018
rs10500770 11 T MeanLDL-C 3.9*10-4 -0.157 0.044 0.17 -0.049 0.036 0.001 0.41 0.017 0.021 0.90 0.006 0.050 0.22 -0.019 0.016
rs10516430 4 RAP1GDS1 T MeanHDL-C 7.2*10-4 -0.139 0.041 0.20 -0.052 0.040 0.001 0.64 -0.010 0.022 Failed Failed Failed 0.02 -0.041 0.017
*The allele on the positive strand of the reference genome was modeled in all analyses.
†Beta refers to the proportion of 1 standard deviation unit change in phenotype (phenotype is sex-specific residual adjusted for age and age2) per copy of the allele modeled.
‡"Failed" refers to SNP genotype failure in the sample.BMC Medical Genetics 2007, 8(Suppl 1):S17 http://www.biomedcentral.com/1471-2350/8/S1/S17
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trait locus explaining 2% of phenotypic variance, 48%
power to detect a locus explaining 1% of the variance, and
13% power to detect a locus explaining 0.5% of the vari-
ance.
With our replication effort, we failed to identify any novel
loci related to blood lipids. At least two potential explana-
tions are possible. First, our study design had limited sta-
tistical power to detect common SNPs that explain ≤1% of
trait variance. In the Diabetes Genetics Initiative genome-
wide association study for blood lipid traits, we recently
showed that for lipid traits, there are few common vari-
ants that explain >2% of the variance and most SNPs
explain <1% of trait variance [25]. To have adequate sta-
tistical power to detect these effects given an initial GWAS
sample size of ~1000, many more markers (i.e., hundreds
of SNPs) will need to be taken to the second and third
stages. Second, the limited genomic coverage of the
Affymetrix 100K array may have limited our ability to rep-
licate previously reported loci and discover novel loci. For
example, using the Affymetrix 500 K array, we recently
identified glucokinase regulatory protein (GCKR) as a
novel locus associated with TG [25]. Of any SNP on the
500 K array, an intronic GCKR SNP (rs780094) explained
the greatest proportion of blood TG variance in the Diabe-
tes Genetics Initiative study. However, on the Affymetrix
100K array, there are no SNPs within the 60 kb spanning
GCKR.
Strengths and limitations
This study is distinguished by the availability of serial
lipid phenotypes over a 30-year time span, the commu-
nity-based nature of the collection, and the routine ascer-
tainment of covariates in a standardized clinical
examination. We acknowledge several limitations. These
include the lack of validation for the imputation method-
ology used to address lipid lowering therapy, limited sta-
tistical power due to sample size, and confinement to a
single ancestral group – whites of European ancestry.
Conclusions & future directions
Using a 100K genome-wide scan, we present association
and linkage results for a rich set of lipid phenotypes in
FHS. This resource may be useful for comparisons with
other GWAS currently in progress. GWAS in FHS using a
denser genome-wide genotyping platform and a better-
powered replication strategy may identify novel loci
underlying blood lipids.
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